China Meheco Group CoSHSE:600056 -2.39%63 EBITDA Margin % is 4.22% as of Mar. 2026, which is 28% below its 10-year median of 5.88. GuruFocus rates SHSE:600056 with a GF Score™ of 63/100 and a GF Value™ of ¥10.49 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 119 Medical Distribution companies, China Meheco Group Co ranks worse than 61.34% on this metric.
China Meheco Group Co (SHSE:600056) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
China Meheco Group Co EBITDA Margin % Related Terms
China Meheco Group Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for China Meheco Group Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600056 vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, China Meheco Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Meheco Group Co EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China Meheco Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where China Meheco Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Meheco Group Co (SHSE:600056) has a EBITDA Margin % of 4.22% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Meheco Group Co and its competitors. This is 28% below median its historical median of 5.88. Over the past decade, China Meheco Group Co's EBITDA Margin % has ranged from 3.41 to 8.61. According to the industry distribution chart, China Meheco Group Co ranks #73 out of 119 companies in the Medical Distribution industry, placing it in the top 61.3%.
Is China Meheco Group Co's EBITDA Margin % too high?
China Meheco Group Co's current EBITDA Margin % of 4.22% is 28% below median its 10-year median of 5.88. Over the past 10 years, this metric has ranged from a low of 3.41 to a high of 8.61. The Medical Distribution industry median EBITDA Margin % is 4.31. China Meheco Group Co's value of 4.22% is 2.1% below this industry median. Based on the distribution chart, China Meheco Group Co ranks #73 out of 119 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, China Meheco Group Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Meheco Group Co's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China Meheco Group Co ranks #73 out of 119 companies for EBITDA Margin %. This places China Meheco Group Co in the lower half of its industry. The industry median EBITDA Margin % is 4.31. China Meheco Group Co's value of 4.22% is 2.1% below this benchmark. Historically, China Meheco Group Co's own EBITDA Margin % has ranged from 3.41 to 8.61 over the past decade. While the company's 10-year median is 5.88 vs. the industry median of 4.31, China Meheco Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Meheco Group Co's current EBITDA Margin % of 4.22% is 2.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Meheco Group Co and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Meheco Group Co's current EBITDA Margin % is 4.22%, which is 28% below median its own 10-year median of 5.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Meheco Group Co stock overvalued right now?
Based on GuruFocus' analysis, China Meheco Group Co (SHSE:600056) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.49, compared to a current price of ¥8.58 — trading 18.2% below its estimated fair value. The current EBITDA Margin % is 4.22%, which is 28% below median its 10-year median of 5.88 and 2.1% below the Medical Distribution industry median of 4.31. China Meheco Group Co's overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For China Meheco Group Co (SHSE:600056), the current EBITDA Margin % is 4.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Meheco Group Co (SHSE:600056) Overvalued in 2026?
Based on GuruFocus' analysis, China Meheco Group Co stock appears to be undervalued.
The current stock price of ¥8.58 is trading 18.2% below its estimated GF Value™ of ¥10.49.
GuruFocus considers China Meheco Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:600056:
EBITDA Margin %: 4.22% (28% below median its 10-year median of 5.88)
GF Value™: ¥10.49 vs. price of ¥8.58 (18.2% below fair value)
Industry Position: 2.1% below the Medical Distribution median (#73 of 119)
No single metric tells the full story. See the SHSE:600056 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Meheco Group Co Ltd is engaged in the distribution and trading of botanical medicines, medical instruments, and pharmaceuticals. It offers botanic medicines and herbal products, as well as exports of natural medicines, including herbs, spices, plant extracts, bee products, and Chinese traditional medicines. The company's business scope covers the whole industry chain, from research and development, cultivation and processing, manufacturing, distribution, and logistics to international trading, academic promotion, and technical service. The corporation provides trading services for customers in the pharmaceutical and chemical field, covering APIs, preparations, biologicals, blood products, and others.
63GF Score
Get the complete analysis for SHSE:600056
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600056 has been successfully added to your 
